Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
O-GlcNAcase (OGA) is an enzyme responsible for the removal of O-linked β-N-acetylglucosamine (O-GlcNAc) from serine and threonine residues on proteins. It plays a crucial role in regulating cellular processes, including gene transcription, energy sensing, and stress response. Dysregulation of OGA has been linked to various diseases, including metabolic disorders, neurodegeneration, and cancer. OGA is a therapeutic target and inhibitors like thiamet-G are used to study its function.
Inhibition of O-GlcNAcase, leading to increased O-GlcNAcylation of proteins
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on O-GlcNAcase (OGA).